合成了含有a啶基和硫ac啶酮单元的新型荧光18-冠-6型配体。通过氧化a啶类似物,以及在K 2 CO 3存在下,将4,5-二羟基ac啶9(10 H)-one和四乙二醇二对甲苯磺酸酯环化,可制得ligand啶配体。使用Lawessons试剂将a啶大环化合物转化为硫ac啶酮配体。还进行了几种前体的合成,从而制备了cri啶酮-18-冠-6荧光团。这些前体对于化学意义上重要的a啶,a啶酮和硫代rid啶酮衍生物也可能是非常有用的结构单元。
合成了含有a啶基和硫ac啶酮单元的新型荧光18-冠-6型配体。通过氧化a啶类似物,以及在K 2 CO 3存在下,将4,5-二羟基ac啶9(10 H)-one和四乙二醇二对甲苯磺酸酯环化,可制得ligand啶配体。使用Lawessons试剂将a啶大环化合物转化为硫ac啶酮配体。还进行了几种前体的合成,从而制备了cri啶酮-18-冠-6荧光团。这些前体对于化学意义上重要的a啶,a啶酮和硫代rid啶酮衍生物也可能是非常有用的结构单元。
Potential antitumor agents. 40. Orally active 4,5-disubstituted derivatives of amsacrine
作者:William A. Denny、Graham J. Atwell、Bruce C. Baguley
DOI:10.1021/jm00369a021
日期:1984.3
5-disubstituted derivatives all showed high activity when administered ip against ip-implanted P-388, but activity varied widely when the compounds were given orally. 4-Methoxy and 4-carbamoyl derivatives proved essentially inactive, whereas 4-methyl and 4-methylcarbamoyl derivatives retained activity. Exceptional oral activity was shown by the 4-methyl-5-methylcarbamoyl derivative, making this amsacrine